News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

DiaSys Corporation (DYX) Presents Additional Patent Claims For Unique In Vitro Assay Technology To Detect And Monitor Kidney Failure Or Malfunction



10/19/2005 5:11:31 PM

DiaSys Corporation (AMEX: DYX) a global healthcare products company announced that it presented additional patent claims for it's unique in vitro assay technology to detect and monitor kidney disease. Kidney malfunction may go undetected by current methods of testing until 80% or more of the kidney is damaged. The technology is quick, easy to use and inexpensive, providing front-line testing for early detection before the kidney degenerates or fails. The claims include monitoring, screening and adjunctive testing for renal (kidney) insufficiency and renal (kidney) failure due to diabetes, hypertension and monoclonal gammopathies. DiaSys Corporation has also presented an additional device claim to include a home testing configuration of its technology.

Read at BioSpace.com


comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES